Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Liposomal anthracyclines

A A Gabizon1

  • 1Sharett Institute of Oncology, Hadassah University Hospital, Jerusalem, Israel.

Hematology/Oncology Clinics of North America
|April 1, 1994
PubMed
Summary
This summary is machine-generated.

Liposome encapsulation enhances chemotherapy efficacy and reduces heart damage. Liposomal anthracyclines show improved tumor drug levels and antitumor effects in preclinical studies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Phase I study of doxil-cisplatin combination chemotherapy in patients with advanced malignancies.

Clinical cancer research : an official journal of the American Association for Cancer Research·2001
Same author

Pegylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy.

Cancer investigation·2001
Same author

Stealth liposomes and tumor targeting: one step further in the quest for the magic bullet.

Clinical cancer research : an official journal of the American Association for Cancer Research·2001
Same author

Reduction of the systemic toxicity of cisplatin by intra-arterial hepatic route administration for liver malignancies.

International journal of cancer·1995
Same author

Prolongation of the circulation time of doxorubicin encapsulated in liposomes containing a polyethylene glycol-derivatized phospholipid: pharmacokinetic studies in rodents and dogs.

Pharmaceutical research·1993
Same author

In vitro cytotoxicity of liposome-encapsulated doxorubicin: dependence on liposome composition and drug release.

Biochimica et biophysica acta·1992
Same journal

Palliative Therapy for Liver and Biliary Neoplasms.

Hematology/oncology clinics of North America·2026
Same journal

Ablative Therapies for Liver Tumors.

Hematology/oncology clinics of North America·2026
Same journal

Pathology of Liver and Biliary Neoplasms.

Hematology/oncology clinics of North America·2026
Same journal

Minimally Invasive Surgery for Liver and Biliary Tract Neoplasms.

Hematology/oncology clinics of North America·2026
Same journal

Surgical Considerations for Primary Liver Neoplasms.

Hematology/oncology clinics of North America·2026
Same journal

Systemic Therapy for Biliary and Liver Neoplasms: Chemotherapy and Immunotherapy.

Hematology/oncology clinics of North America·2026
See all related articles

Area of Science:

  • Oncology
  • Pharmacology
  • Drug Delivery Systems

Background:

  • Anthracyclines are potent chemotherapeutic agents with significant cardiotoxicity.
  • Liposomal drug delivery aims to improve therapeutic index by altering drug pharmacokinetics.

Purpose of the Study:

  • To evaluate the efficacy and cardiotoxic effects of liposome-encapsulated anthracyclines.
  • To assess the impact of liposomal delivery on tumor drug levels and antitumor activity.
  • To investigate the clinical pharmacokinetics of liposomal doxorubicin.

Main Methods:

  • Preclinical experiments in mouse models using liposome-encapsulated anthracyclines.
  • Assessment of cardiotoxic effects and antitumor efficacy.
  • Clinical pharmacokinetic studies of doxorubicin delivered via liposomes.

Related Experiment Videos

Main Results:

  • Liposome encapsulation significantly decreased cardiotoxicity of anthracyclines in preclinical studies.
  • Long-circulating liposomes enhanced tumor drug levels and antitumor efficacy in mouse models.
  • Liposomal doxorubicin demonstrated altered clinical pharmacokinetics compared to conventional formulations.

Conclusions:

  • Liposomal delivery of anthracyclines shows promise for reducing cardiotoxicity.
  • Enhanced tumor drug delivery and efficacy are observed with liposomal anthracyclines.
  • Ongoing clinical trials will determine the therapeutic superiority of liposomal anthracycline preparations.